148. Barros-Álvarez X., Turley S., M. Ranade R.M., Gillespie J.R., Duster N.A., Verlinde C.M.J. , Fan E., Buckner F.S., Hol W.G.J.(2018).
The crystal structure of the drug target Mycobacterium tuberculosis methionyl-tRNA synthetase in complex with a catalytic intermediate.
Acta Cryst. F: 245-254. [PMID: 29633973]
147. Cardew E.M., Verlinde C.L.M.J., Pohl, E.(2018).
The Calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design.
Parasitology 145: 210-218. [PMID: 29191253]

146. Faghih O., Zhang Z., Ranade R.M., Gillespie J.R., Creason S.A., Huang W., Shibata S., Barros-Álvarez X., Verlinde C.L.M.J., Hol W.G.J., Fan E., Buckner F.S. (2017).
Development of methionyl-tRNA synthetase inhibitors as antibiotics for Gram-positive bacterial infections.
Antimicrob. Agents Chemother. 61: e00999-17. [PMID: 28848016]
145. Huang W., Zhang Z., Ranade R.M., Gillespie J.R., Barros-Álvarez X., Creason S.A., Shibata S., Verlinde C.L.M.J., Hol W.G.J., Buckner F.S., Fan E. (2017).
Optimization of a binding fragment targeting the "enlarged methionine pocket" leads to potent Trypanosoma brucei methionyl-tRNA synthetase inhibitors.
Bioorg. Med. Chem. Lett. 27: 2702-2707. [PMID: 28465105]
144. Barros-Álvarez X., Kerchner K.M., Koh C.Y., Turley S., Pardon E., Steyaert J., Ranade R.M., Gillespie J.R., Zhang Z., Verlinde C.L.M.J., Fan E., Buckner F.S., Hol W.G.J.(2017).
Leishmania donovani tyrosyl-tRNA synthetase structure in complex with a tyrosyl adenylate analog and comparisons with human and protozoan counterparts.
Biochimie 138: 124-136. [PMID: 28427904]

143. Huang W., Zhang Z., Barros-Alvarez X., Koh, C.Y., Ranade R.M., Gillespie J.R., Creason S.A., Shibata S., Verlinde C.L.M.J., Hol W.G.J., Buckner F.S., Fan E. (2016).
Structure-guided design of novel Trypanosoma brucei methionyl-tRNA synthetase inhibitors.
Eur. J. Med. Chem. 124: 1081-1092. [PMID: 27788467]
142. Specific inhibitors of methionyl-trna synthetase. Patent Appl.: WO 2016029146 A1
141. Zhang Z., Koh C.Y., Ranade R.M., Shibata S., Gillespie J.R., Hulverson M.A., Huang W., Nguyen J., Pendem N., Gelb, M.H., Verlinde C.L.M.J.,
Hol W.G.J., Buckner F.S., Fan E. (2016).
5-Fluoro-imidazo[4,5-b]pyridine is a privileged fragment that conveys bioavailability to potent trypanosomal methionyl-tRNA synthetase inhibitors.
ACS Infect. Dis. 2: 399-404. [PMID: 27627628]


140. Ranade R.M., Zhang Z., Gillespie J.R., Shibata S., Verlinde C.L.M.J., Fan E., Hol W.G.J., Buckner F.S. (2015).
Inhibitors of Methionyl-tRNA Synthetase have potent activity on Giardia intestinalis trophozoites.
Antimicrob. Agents Chemother. 59: 7128-7131. [PMID: 26324270]
139. Koh C.Y., Kallur Siddaramaiah L., Ranade R., Nguyen J., Jian T., Zhang Z., Gillespie J.R., Buckner F.S., Verlinde C.L.M.J., Fan E., Hol W.G.J. (2015).
A binding hotspot in the Trypanosoma cruzi histidyl-tRNA synthetase revealed by fragment-based crystallographic cocktail screens.
Acta Cryst. D71: 1684-1698. [PMID: 26249349]
138. Pedró-Rosa L., Buckner F.S., Ranade R.M., Eberhart C., Madoux F., Gillespie J.R., Koh C.Y., Brown S., Lohse J., Verlinde C.L.M.J., Fan E., Bannister T., Scampavia L., Hol W.G.J., Spicer T., Hodder P. (2015).
Identification of Potent Inhibitors of the Trypanosoma brucei Methionyl-tRNA Synthetase Inhibitors via High Throughput Orthogonal Screening.
J. Mol. Screening. 20: 122-130. [PMID: 25163684]


137. Koh C.Y., Kim J.E., Wetzel A.B., de van der Schueren W.J., Shibata S., Ranade R.M., Liu J., Zhang Z., Gillespie J.R., Buckner F.S., Verlinde C.L.M.J., Fan E., Hol W.G.J. (2014).
Structures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness.
PLOS Negl. Trop. Dis. 8: e2775. [PMID: 24743796]
136. Vidadala R.S., Ojo K.K., Johnson S.M., Zhang Z., Leonard S.E., Mitra A., Choi R., Reid M.C., Keyloun K.R., Fox A.M., Kennedy M., Silver-Brace T., Hume J.C., Kappe S., Verlinde C.L.M.J., Fan E., Merritt E.A., Van Voorhis W.C., Maly D.J. (2014).
Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes.
Eur. J. Med. Chem. 74: 562-573. [PMID: 24531197]
135. Zhang Z., Ojo K.K., Vidadala R., Wenlin H., Geiger J., Scheele S., Choi R., Reid, M., Keyloun K., Rivas K., Kallur L.S., Comess K., Robinson K., Merta P., Kifle L., Hol W.G.J., Parsons, M., Merritt E.A., Maly D.J., Verlinde C.L.M.J., Van Voorhis W.C., Fan E. (2014).
Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold.
ACS Med. Chem. Lett. 5: 40-44. [PMID: 24494061]
134. Ojo K.K., Eastman R.T., Vidadala R., Zhang Z., Rivas K.L., Choi R., Lutz J.D., Reid M.L., Fox A.M.W., Hulverson M.A., Kenndey M., Isoherranen N., Kim L.M., Comess K.M., Kempf D.J., Verlinde C.L.M.J., Su X., Kappe S., Maly D.J., Fan E., Van Voorhis W.C. (2014).
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
J. Inf. Dis. 209: 275-284. [PMID: 24123773]


133. Suryadevara P.K., Racherla K.K., Olepu S., Norcross N., Tatipaka H.B., Arif J.A., Planer J.D., Lepesheva, G.I., Verlinde C.L.M.J., Buckner F.S., Gelb M.H. (2013).
Dialkylimidazole inhibitors of Trypanosoma cruzi lanosterol 14α-demethylase as anti-Chagas disease agents.
Bioorg. Med. Chem. Lett. 23: 6492–6499. [PMID: 24120539]
132. Khamrui S., Turley S., Pardon E., Steyaert J., Fan E., Verlinde C.L.M.J., Bergman L.W., Hol W.G.J. (2013).
The structure of the D3 domain of Plasmodium falciparum myosin tail interacting protein MTIP in complex with a nanobody.
Mol. Biochem. Parasitol. 190 : 87-91. [PMID: 23831371]
131. Koh C.Y.,Kim J.E., Napoli A.J., Verlinde C.L.M.J., Fan E., Buckner F.S., Van Voorhis W.C., Hol W.G.J. (2013).
Crystal structures of Plasmodium falciparum cytosolic tryptophanyl-tRNA synthetase and its potential as a target for structure-guided drug design.
Mol. Biochem. Parasitol. 189: 26-32. [PMID: 23665145]
130. Ranade R.M., Gillespie J.R, Shibata S., Verlinde C.L.M.J., Fan E., Hol W.G.J., and Buckner F.S. (2013).
Induced Resistance to Methionyl-tRNA Synthetase Inhibitors in Trypanosoma brucei is Due to Overexpression of the Target.
Antimicrob. Agents Chemother. 57: 3021-3028. [PMID: 23587950]


129. Larson E.T., Kim J.E., Napuli A.J., Verlinde C.L.M.J., Fan E., Zucker F.H., Van Voorhis W.C., Buckner F.S., Hol W.G.J., Merritt E.A. (2012).
Structure of the prolyl-tRNA synthetase from the eukaryotic pathogen Giardia lamblia.
Acta Cryst. D68: 1194-1200. [PMID: 22948920]
128. Buckner F.S, Bahia M.T., Suryadevara P.K., White K.L., Shackleford D.M., Chennamaneni N.K., Hulverson M., Laydbak J., Chatelain E., Scandale I., Verlinde C.L.M.J., Charman S.A., Lepesheva G.I., Gelb M.H. (2012).
Pharmacological characterization, structural studies, and in vivo Activity of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib.
Antimicrob. Agents Chemother. 56: 4914-4921. [PMID: 22777048]
127. Koh C.Y., KimJ.E., Shibata S., Ranade R.M., Yu M., Liu J., Gillespie J.R., Buckner F.S., Verlinde C.L.M.J., Fan E., Hol W.G.J. (2012).
Distinct states of methionyl tRNA-synthetase indicate binding of inhibitors by conformational selection.
Structure 20: 1681-1691. [PMID: 22902861]
126. Zhang Z., Ojo K.K., Johnson S.M., Larson E.T., He P., Geiger J.A., Castellanos-Gonzalez A., White A.C.Jr., Parsons M., Merritt E.A., Maly D.J., Verlinde C.L.M.J., Van Voorhis W.C., Fan E.(2012).
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
Bioorg. & Med. Chem. Lett. 22:5264-5267. [PMID: 22795629]
125. Shibata S., Gillespie J.R., Ranade R.M., Koh C.Y., Kim J.E, Laydbak J.U., Zucker F.H., Hol W.G.J., Verlinde C.L.M.J., Buckner F.S., Fan E.(2012).
Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization.
J. Med. Chem. 55: 6342-6351. [PMID: 22720744]
124. Ojo K.K., Pfander C., Mueller N.R., Burstroem C., Larson E.T., Bryan C.M., Fox A.M.W., Reid M.C., Johnson S.M., Murphy R.C., Kennedy M., Leibly D.J., Hewitt S.N., Verlinde C.L.M.J., Kappe S., Merritt E.A., Maly D.J., Billker O., Van Voorhis W.C. (2012).
Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors .
J. Clin. Invest. 122: 2301-2305. [PMID: 22565309]
123. Larson E.T., Ojo K.K., Murphy R.C., Johnson S.M., Zhang Z., Kim J.E., Leibly D.J., Fox A.M.W., Reid M.C., Dale E.J., Perera, B.G.K., Kim J., Hewitt S.N., Hol W.G.J., Verlinde C.L.M.J., Fan E., Van Voorhis W.C., Maly D.J., Merritt E.A. (2012).
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
J. Med. Chem. 55:2803-2810. [PMID: 22369268]


122. Shibata S., Zhang Z., Korotkov K.V., Rosa J.D., Napuli A., Kelley A., Mueller N., Ross J., Zucker F., Buckner F.S., Merritt E.A., Verlinde C.L.M.J.,
Van Voorhis W.C., Hol W.G.J., Fan E. (2011).
Screening Fragment-Based Compound Library Using Ultrafiltration.
Anal. Bioanal. Chem. 401: 1589-1595. [PMID: 21750879]
121. Larson E.T., Kim J.E., Castaneda L.J., Napuli A.J., Zhang Z., Fan E., Zucker F.H., Verlinde C.L.M.J., Buckner F.S., Van Voorhis W.C., Hol W.G.J., Merrit E.A. (2011).
Tyrosyl tRNA-synthetase from the eukaryote Leishmania major is monomeric but forms an intrinsically asymmetric pseudo-dimer.
J. Mol. Biol. 409: 159-176. [PMID: 21420975]
120. Shibata S., Gillespie J.R., Kelley A.M., Napuli A.J., Zhang Z., Kovzun K.V., Pefley R.M., Lam J., Zucker F., Van Voorhis W.C., Merritt E.A., Hol W.G.J., Verlinde C.L.M.J., Fan E., Buckner F.S. (2011). Selective inhibitors of methionyl-tRNA synthetase have potent activity on Trypanosoma brucei infection in mice. Antimicrob. Agents Chemother. 55: 1982-1989. [PMID: 21282428]
119. Merritt E.A., Arakaki T.L., Gillespie R., Napuli A.J., Kim J.E., Buckner F.S., Van Voorhis W.C., Verlinde C.L.M.J., Fan E., Zucker F., Hol W.G.J. (2011). Crystal structures of three protozoan homologs of tryptophanyl-tRNA synthetase. Mol. Biochem. Parasitol.177: 20-28. [PMID: 21255615]
118. Ojo K.K., Arakaki T.L., Napuli A.J., Kishore K., Keyloun K.R., Zhang L., Hol W.G.J., Verlinde C.L.M.J., Merritt E.A. Van Voorhis W.C. (2011).
Structure Determination of Glycogen Synthase Kinase-3 from Leishmania major Explains a Distinct Inhibitor Structure Activity Relationship Compared with Trypanosoma brucei GSK-3.
Mol. Biochem. Parasitol.176: 98-108. [PMID: 21195115]
117. Larson E.T., Kim J.E., Zucker F., Kelley A., Mueller N., Napuli A.J., Verlinde C.L.M.J., Fan E., Buckner F.S., Van Voorhis W.C., Merritt E.A., Hol W.G.J. (2011).
Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate.
Biochimie 93: 570-582. [PMID: 21144880]


116. Murphy R.C., Ojo K.K., Larson E.T., Castellanos-Gonzalez A., Perera B.G.K., Keyloun K.R., Kim J.E., Bhandari J.G., Muller N.R., Verlinde C.L.M.J., Nakazawa S.H., Hol W.G.J., Buckner F.S., Napuli A., White C.A., Merritt E.A., Van Voorhis W.C., Maly D.J. (2010).
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii.
ACS Med. Chem. Lett. 1: 331-335. [PMID: 21116453]
115. Arakaki T.L., Carter M., Napuli A.J., Verlinde C.L.M.J., Fan E., Zucker F., Buckner F.S., Van Voorhis W.C., Hol W.G.J., Merritt E.A. (2010).
The structure of tryptophanyl-tRNA synthetase from Giardia lamblia reveals divergence from eukaryotic homologs.
J. Struct. Biol. 171: 238-243. [PMID: 20438846]
114. Kraus J.M., Tatipaka H.B., McGuffin S.A., Chennamaneni N.K., Arif J., Verlinde C.L.M.J., Buckner F.S., Gelb M.H. (2010).
Second generation analogs of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.
J.Med.Chem. 53: 3887-98. [PMID: 20429511]
113. Zucker F.H., Stewart C., Rosa J.D., Kim J., Zhang L., Xiao L., Ross J., Napuli A.J., Mueller N., Castaneda L.J., Nakazawa Hewitt S.R., Arakaki T.L., Larson E.T., Subramanian E., Verlinde C.L.M.J., Fan E., Buckner F.S., Van Voorhis W.C., Merritt E.A., Hol W.G.J. (2010).
Prediction of protein crystallization outcome using a hybrid method.
J. Struct. Biol. 171: 64-73. [PMID: 20347992]
112. Ojo K.K., Larson E.T., Keyloun K.R., Castaneda L.J., DeRocher A.E., Inampudi K.K., Kim J.E., Arakaki T.L., Murphy R., Zhang L., Maly D.J., Verlinde C.L.M.J., Buckner F.S., Parsons M., Hol W.G.J., Merritt E.A., Van Voorhis W.C. (2010).
A Unique Variation of the ATP binding site makes Toxoplasma gondii Calcium-Dependent Protein Kinase 1 a drug target for selective kinase inhibitors.
Nature Str. Mol. Biol. 17: 602-607. [PMID: 20436472]
111. Merritt E.A., Arakaki T.L., Gillespie J.R., Larson E.T., Kelley A., Mueller N., Napuli A.J., Kim J., Zhang L., Verlinde C.L.M.J. , Fan E., Zucker F., Buckner F.S., Van Voorhis W.C., Hol W.G.J. (2010).
Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs.
J. Mol. Biol. 397: 481-494. [PMID: 20132829]
110. Galland N., de Walque S., Voncken F.G.J., Verlinde C.L.M.J., Michels P.A.M. (2010).
An internal sequence targets Trypanosoma brucei triosephosphate isomerase to glycosomes.
Mol. Biochem. Parasitol. 171: 45-49. [PMID: 20138091]
109. Michels, P.A.M., Verlinde L.M.J., Fothergill-Gilmore L.A. (2010).
"Glycolytic Enzymes" In: Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester. [DOI: 10.1002/9780470015902.a0000621.pub2]
108. Larson E.T., Mudeppa D.G., Mueller N., Napuli A.J., Gillespie J.R., Arif J.A., Ross J., Arakaki T.L., Lauricella A., DeTitta G., Luft J., Zucker F., Verlinde C.L.M.J. , Fan E., Buckner F.S., Van Voorhis W.C., Rathod P.K., Hol W.G.J., Merritt E.A. (2010).
The crystal structure and activity of a putative trypanosomal nucleoside phosphorylase reveal it to be a homodimeric uridine phosphorylase.
J. Mol. Biol. 396: 1244-1259. [PMID: 20070944]
107. Merritt E.A., Arakaki T.L., Larson E.T., Kelley A., Mueller N., Napuli A.J., Zhang L., DeTitta G., Luft J., Verlinde C.L.M.J. , Fan E., Zucker F.,
Buckner F.S., Van Voorhis W.C., Hol W.G.J. (2010).
Crystal structure of Aspartyl-tRNA synthetase from Entamoeba histolytica.
Mol. Biochem. Parasitol. 169: 95-100. [PMID: 19874856]


106. Verlinde C.L.M.J., Fan E., Shibata S., Zhang Z., Sun Z., Deng W., Ross J., Kim J., Xiao L., Arakaki T., Bosch J., Caruthers J.M., Larson E.T., LeTrong I., Napuli A., Kelley A., Mueller N., Zucker F., Van Voorhis W.C., Buckner F.S., Merritt E.A., Hol W.G.J. (2009).
Fragment-based cocktail crystallography by the Medical Structural Genomics of Pathogenic Protozoa Consortium.
Curr. Topics Med. Chem. 9: 1678-1687. [PMID: 19929835]
105. Crowther G. J., Napuli A.J., Thomas A.P., Chung D.J., Kovzun K.V., Leibly D.J., Castaneda L.J., Bhandari J., Damman C.J., Hui R., Hol W.G.J., Verlinde C.L.M.J., Zhang Z., Fan E., Van Voorhis W.C. (2009).
Buffer Optimization of Thermal Melt Assays of Plasmodium Proteins for Detection of Small-Molecule Ligands.
J. Biomol. Screening 14: 700-707. [PMID: 19470714]
104. Suryadevara P.K., Olepu S., Lockman J.W., Ohkanda J., Karimi M., Verlinde C.L.M.J. , Kraus J.M., Schoepe J., Van Voorhis W.C., Hamilton A.D., Buckner F.S., Gelb M.H. (2009).
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease.
J. Med. Chem. 52: 3703-3715. [PMID: 19463001]
103. Kraus J.M., Verlinde C.L.M.J., Karimi M., Lepesheva G., Gelb M.H., Buckner F.S. (2009).
Rational modification of a candidate cancer drug for use against Chagas disease.
J. Med. Chem. 52: 1639-1647. [PMID: 19239254]


102. Kline T., Jackson S.R., Deng W., Verlinde C.L.M.J., Miller S.I. (2008).
Design and Synthesis of bis-Carbamate Analogs of Cyclic bis-(3'-5')-Diguanylic Acid (c-di-GMP) and the Acyclic Dimer pGpG.
Nucleosides Nucleotides Nucleic Acids 27: 1282-1300. [PMID: 19003573]
101. Oslund R.C., Cermak N., Verlinde C.L.M.J., Gelb M.H. (2008).
Simplified YM-26734 inhibitors of secreted phospholipase A(2) group IIA. Bioorg. Med. Chem. Lett. 18: 5415-5419. [PMID: 18818074]
100. Deng W., Verlinde C.L.M.J. (2008).
Evaluation of Different Virtual Screening Programs for Docking in a Charged Pocket.
J. Chem. Inf. Mod. 48: 2010-2020. [PMID: 18821750]
99. Wang H., Liu Y., Li Z., Tuve S., Stone D., Kalyushniy O., Shayakhmetov D., Verlinde C.L.M.J., Stehle T., McVey J., Baker A., Peng K.W., Roffler S., Lieber A. (2008).
In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46.
J. Virol. 82: 10567-79. [PMID: 18753195]
98. Aguero F., Al-Lazikani B., Aslett M., Berriman M., Buckner F.S., Campbell R.K., Carmona S., Carruthers I.M., Chan A.W.E., Chen F., Crowther G.J., Doyle M.A., Hertz-Fowler C., Hopkins A.L., McAllister G., Nwaka S., Overington J.P., Pain A., Paolini G.V., Pieper U., Ralph S.A., Riechers A., Roos D.S., Sali A., Shanmugam D., Suzuki T., Van Voorhis W.C., Verlinde C.L.M.J. (2008).
Genomic-scale prioritization of drug targets: the TDR Targets database.
Nature Rev. Drug Discov. 7: 900-907. [PMID: 18927591]
97. Larson E.T., Deng W., Krumm B.E., Napuli A., Mueller N., Van Voorhis W.C., Buckner F.S., Fan E., Lauricella A., Detitta G., Luft J., Zucker F.,
Hol W.G.J., Verlinde C.L.M.J., Merritt E.A. (2008).
Structures of Substrate- and Inhibitor-Bound Adenosine Deaminase from a Human Malaria Parasite Show a Dramatic Conformational Change and Shed Light on Drug Selectivity.
J. Mol. Biol. 381: 975-988. [PMID: 18602399]
96. Ojo K.K., Gillespie J.R., Riechers A.J., Napuli A.J., Verlinde C.L.M.J. , Buckner F.S., Gelb M.H., Domostoj M., Wells S., Scheer A., Wells T., Van Voorhis W.C. (2008).
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.
Antimicrob. Agents Chemother. 52: 3710-3717. [PMID: 18644955]
95. Liu J., Begley D., Mitchell D.D., Verlinde C.L.M.J., Hol W.G.J., Varani G., Fan E. (2008).
Probing multivalent ligand interactions with multimeric cholera toxin using saturation transfer difference NMR.
Chem. Biol. Drug Res.71: 408-419. [PMID: 18373548]
94. Fan E., Baker D., Fields S., Gelb M., Buckner F., Van Voorhis W., Phizicky E., Dumont M., Mehlin C., Grayhack E., Sullivan M., Verlinde C., DeTitta G., Meldrum D.R., Merritt E., Earnest T., Zucker F., Myler P.J., Schoenfeld L., Kim D., Worthey L., LaCount D., Vignali M., Li J., Mondal S., Massey A., Brian Carroll B., Gulde S., Luft J., DeSoto L., Holl M., Caruthers J., Bosch J., Robien M., Arakaki T., Holmes M., Le Trong I., Hol W.G.J. (2008). "Structural Genomics of Pathogenic Protozoa" In 'Structural Proteomics: High throughput Methods'. Eds. Kobe B., Guss M., Huber T. Humana Press, Totowa, NJ, USA, 2008, pp. 497-513. [PMID: 18542886]
93. Arakaki T.L., Buckner F.S., Gillespie J.R., Malmquist N.A., Phillips M.A., Kalyuzhniy O., Luft J.R., De Titta G.T., Verlinde C.L.M.J.,
Van Voorhis W.C., Hol W.G.J., Merritt E.A. (2008).
Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies.
Mol. Microbiol. 68: 37-50. [PMID: 18312275 ].
92. Olepu S., Suryadevera P.K., Rivas K., Verlinde C.L.M.J., Chakrabarti D., Van Voorhis W.C., Gelb M.H. (2008).
2-Oxo-tetrahydro-1,8-naphthyridine-Based Protein Farnesyltransferase Inhibitors as Antimalarials.
Bioorg. Med. Chem. Lett. 18: 494-497. [PMID: 18077162]
91. Bulbule V., Rivas K., Verlinde C.L.M.J., Van Voorhis W.C., Gelb M.H. (2008).
2-Oxo-Tetrahydroquinoline-Based Anti-Malarials with High Potency and Metabolic Stability.
J. Med. Chem. 51: 384-387. [PMID: 18198825]


90. Wang H., Liaw Y.C., Stone D., Kalyuzhniy O., Amiraslanov I., Tuve S., Verlinde C.L., Shayakhmetov D., Stehle T., Roffler S., Lieber A. (2007).
Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob.
J. Virol. 81: 12785-12792. [PMID: 17898059 ]
89. Bendale P., Olepu S., Suryadevara P.K., Bulbule V., Rivas K., Nallan L., Smart B., Yokoyama K., Ankala S., Pendyala P.R., Floyd D., Lombardo L.J., Williams D.K., Buckner F.S., Chakrabarti D., Verlinde C.L.M.J., Van Voorhis W.C., Gelb M.H. (2007).
Second Generation Tetrahydroquinoline-Based Protein Farnesyltransferase Inhibitors as Anti-Malarials.
J. Med. Chem. 50: 4585-4605. [PMID: 17722901]
88. Van Voorhis W.C., Rivas K.L., Bendale P., Nallan L., Horney C., Barrett L.K., Bauer K.D., Smart B.P., Ankala S., Hucke O., Verlinde C.L., Chakrabarti D., Strickland C., Yokoyama K., Buckner F.S., Hamilton A.D., Williams D.K., Lombardo L.J., Floyd D., Gelb M.H. (2007).
Tetrahydroquinoline Plasmodium falciparum protein farnesyltransferase inhibitors: Efficacy, pharmacokinetics, and metabolism.
Antimicrob. Agents Chemother. 51: 3659-3671 [PMID: 17606674]
87. Cho H., Verlinde C.L.M.J., Weiner A.M. (2007).
Reengineering CCA-adding enzymes to function as (U,G)- or dCdCdA-adding enzymes, or poly(C,A) and poly(U,G) polymerases.
Proc. Natl. Acad. Sci. USA 104: 54-59. [PMID: 17179213]


86. Eastman R.T., White J., Hucke O., Yokoyama K., Verlinde C.L.M.J. , Gelb M.H., Rathod P.K., Van Voorhis W.C. (2006).
Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase.
Mol. Biochem. Pharmacol. 152: 66-71. [PMID: 17208314]
85. Bosch J., Robien M.A., Mehlin C., Boni E., Riechers A., Buckner F.S., Van Voorhis W.C., Myler P.J., Worthey E.A., DeTitta G., Luft J.R., Lauricella A., Gulde S., Anderson L.A., Kalyuzhniy O., Neely H.M., Ross J., Earnest T.N., Michael Soltis, Lori Schoenfeld, Zucker F., Merritt E.A., Fan E., Verlinde C.L.M.J., Hol W.G.J.(2006).
Identifying Novel Lead Compounds For Inhibiting Nucleoside 2-deoxyribosyltransferase In Trypanosoma brucei by Fragment Cocktail Crystallography.
J. Med. Chem. 49: 5939-5946. [PMID: 17004709 ].
84. Holmes M.A., Buckner F.S., Van Voorhis W.C., Verlinde C.L., Mehlin C., Boni E., DeTitta G., Luft J., Lauricella A., Anderson L., Kalyuzhniy O., Zucker F., Schoenfeld L.W., Earnest T.N., Hol W.G., Merritt E.A. (2006).
Structure of ribose 5-phosphate isomerase from Plasmodium falciparum.
Acta Cryst. F62:427-431. [PMID: 16682767]
83. Robien M.A., Bosch J., Buckner F.S., VanVoorhis W.C., Worthey E.A., Mehlin C., Boni E.E., Kaluzhiniy O., Anderson L., Lauricella A., Gulde S., Luft J.R., DeTitta G., Caruthers J.M., Hodgson K.O., Soltis M., Zucker F., Verlinde C.L.M.J., Merritt E.A., Schoenfeld L.W., Hol W.G.J. (2006).
Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 A resolution reveals intruiging extra electron density in the acive site.
Proteins 62: 570-577. [PMID: 16345073 ].


82. Hucke O., Gelb M.H., Verlinde C.L.M.J., Buckner F.S. (2005).
The Protein Farnesyltransferase Inhibitor Tipifarnib as a new Lead for the Development of Drugs against Chagas Disease.
J. Med. Chem. 48 : 5415-5418. [PMID: 16107140 ]
81. Glenn M.P., Chang S.Y., Hucke O., Verlinde C.L.M.J. , Rivas K., Pickeral C., Yokoyama K., Buckner F.S., Pendyala P.R., Chakrabarti D., Gelb M., Van Voorhis W.C., Sebti S., Hamilton A.D. (2005).
Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites.
Angw. Chem. Int. Ed. Engl. 44: 4903-4906. [PMID: 16007716]
80. Shao B., Belaaouaj A., Verlinde C.L.M.J. , Fu X., Heinecke J.W. (2005).
Methionine sulfoxide and proteolytic cleavage contribute to the inactivation of cathepsin G by hypochlorous acid: An oxidative mechanism for regulation of serine proteinases by myeloperoxidase.
J. Biol. Chem. 280: 29311-29321. [PMID: 15967795]
79. Tai G., Farin F., Rieder M.J., Dreisbach A.W., Veenstra D.L., Verlinde C.L.M.J., Rettie A.E. (2005).
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.
Pharmacogenet Genomics 15: 475-481. [PMID: 1597079]
78. Eastman R.T., White J., Hucke O., Bauer K., Yokoyama K., Nallan L., Chakrabarti D., Verlinde C.L.M.J., Gelb M.H., Rathod P.K., Van Voorhis W.C. (2005). Resistance to a Protein Farnesyltransferase Inhibitor in Plasmodium falciparum.
J. Biol. Chem. 280: 13554-13559. [PMID: 15661734]
77. Liu J., Zhang Z., Tan X., Hol W.G.J., Verlinde C.L.M.J., Fan E. (2005).
Structure-based design of a bifunctional molecule that promotes multivalent hetero-dimerization of protein pairs: enhancing the ability of a monovalent ligand to inhibit surface receptor-binding by cholera toxin B pentamer.
J. Am. Chem. Soc. 127: 2044-2045. [PMID: 15713072]
76. Cho H.D., Verlinde C.L.M.J., Weiner A.M. (2005).
Archaeal CCA-adding enzymes: Central role of a highly conserved beta-turn motif inRNA polymerization without translocation.
J. Biol. Chem. 280: 9555-9566. [PMID: 15590678]


75. Abel E.A., Lyon R.P., Bammler T.K., Verlinde C.L.M.J., Laud S.S., Monks T.J., Eaton D.L. (2004).
Estradiol metabolites as isoform-specific inhibitors of human glutathione S-transferases.
Chem. Biol. Interact. 151: 21-32. [PMID: 15607759]
74. Zhang Z., Liu J., Verlinde C.L.M.J., Hol W.G.J., Fan E. (2004).
Large Cyclic Peptides as Cores of Multivalent Ligands: Application to Inhibitors of Receptor Binding by Cholera Toxin.
J. Org. Chem. 69: 7737-7740. [PMID: 15498005.]
73. Pickens J., Mitchell D., Liu J., Zhang Z., Verlinde C.L.M.J., Hol W.G.J., Fan E. (2004).
Non-spanning bivalent ligands as improved surface receptor-binding inhibitors of the cholera toxin B pentamer.
Chem. & Biol.11: 205-215. [PMID: 15380181]
72. Abel E.L., Opp S.M., Verlinde C.L.M.J., Bammler T.K., Eaton D.L. (2004).
Characterization of atrazine biotransformation by humane and murine glutathione-S-transferases.
Toxicol. Sci.80: 230-238. [PMID:  15115887]


71. Fan E., O'Neal C.J., Mitchell D.D., Robien M.A., Zhang Z., Pickens J.C., Tan X.J., Korotkov K., Roach C., Krumm B., Verlinde C.L.M.J. , Merritt E.A., Hol W.G.J. (2003).
Structural Biology and Structure-based Inhibitor Design of Cholera Toxin and Heat-labile Enterotoxin.
Int. J. Med. Microbiol. 294: 217-223. [PMID: 15532979]
70. Buckner F.S., Joubert B.M., Boyle, S.M., Eastman R.T., Verlinde C.L.M.J. , Matsuda S.P.T. (2003).
Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase.
Mol. Biochem. Parasitol. 32: 75-81. [PMID: 14599667]
69. Hu X., Nguyen K.T., Verlinde C.L.M.J., Hol W.G., Pei D. (2003).
Structure-Based Design of a Macrocyclic Inhibitor for Peptide Deformylase.
J. Med. Chem. 46: 3771-3774. [PMID: 12930137]
68. Auerbach S.S., Ramsden R., Stoner M.A., Verlinde C.L.M.J., Hassett C., Omiecinski C.J. (2003).
Alternatively-spliced isoforms of the human constitutive androstane receptor.
Nucleic Acids Res. 31: 3194-3207. [PMID: 12799447].
67. Chen D.H., Brkanac Z., Verlinde C.L.M.J., Tan X.J., Bylenok L., Nochlin D., Matsushita M., Lipe H., Wolff J., Fernandez M., Cimino P.J., Bird T.D., Raskind W.H. (2003).
Missense Mutations in the Regulatory Domain of PKCgamma: A New Mechanism for Dominant Nonepisodic Cerebellar Ataxia.
Am. J. Hum. Gen. 72: 839-849. [PMID: 12644968]


66. Zhang Z., Merritt E.A., Ahn M., Roach C., Hou Z., Verlinde C.L.M.J., Hol W.G.J., Fan E. (2002).
Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin.
J. Am. Chem. Soc. 124: 12991-12998. [PMID: 12405825]
65. Verlinde C.L.M.J., Bressi J.C., Choe J., Suresh S., Buckner F.S., Van Voorhis W.C., Michels P.A.M., Gelb M.H., Hol W.G.J. (2002). Protein structure-based design of anti-protozoal drugs. J. Braz. Chem. Soc.13: 843-844.
64. Pickens J.C., Merritt E.A., Ahn M., Verlinde C.L.M.J., Hol W.G.J., Fan E. (2002).
Anchor-Based Design of Improved Cholera Toxin and E. coli Heat-Labile Enterotoxin Receptor Binding Antagonists that Display Multiple Binding Modes.
Chem Biol. 9: 215-24. [PMID: 11880036]


63. Hol W.G.J., Verlinde C.L.M.J. (2001).
Crystallography and Medicine. In 'International Tables of Crystallography. Vol. F. Crystallography of Biological Macromolecules' , Eds. Rossmann M.G., Arnold E., Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 10-43.
62. Bressi J.C., Verlinde C.L.M.J., Aronov A.M, Le Shaw M., Shin S.S., Nguyen L.N., Suresh S.,Buckner F.S., Van Voorhis W.C. , Kuntz I.D., Hol W.G.J., Gelb M.H. (2001).
Adenosine Analogues as Selective Inhibitors of Glyceraldehyde-3-phosphate Dehydrogenase of Trypanosomatidae via Structure-Based Drug Design.
J. Med. Chem.: 2080-2093. [PMID:11405646]
61. Suresh S., Bressi J.C., Kennedy K.J., Verlinde C.L.M.J., Gelb M.H., Hol W.G.J. (2001).
Conformational changes in Leishmania mexicana glyceraldehyde-3-phosphate dehydrogenase induced by designed inhibitors.
J. Mol. Biol. 309, 423-435. [PMID: 11371162]
60. Verlinde C.L.M.J., Hannaert V. Blonski C., Willson M., Perie J.J., Fothergill-Gilmore L., Opperdoes F.R., Gelb M.H., Hol W.G.J., P.A.M. Michels (2001).
Glycolysis as a target for the design of new anti-trypanosome drugs.
Drug Resistance Updates 4: 50-65. [PMID: 11512153]


59. Cideciyan A.V., Haeseleer F., Fariss R.N., Aleman T.S., Jang G.F., Verlinde C.L.M.J, Marmor M.F., Jacobson S.G., Palczewski K. (2000).
Rod and cone visual cycle consequences of a null mutation in the 11-cis-retinol dehydrogenase gene in man.
Vis. Neurosci. 17: 667-678. [PMID:11153648]
58. Fan E., Merritt E.A., Verlinde C.L.M.J., Hol W.G.J. (2000).
AB5 toxins: Structures and inhibitor design.
Curr. Op. Struct. Biol. 10: 680-686 [PMID: 11114505]
57. Sokal I., Li N., Verlinde C.L.M.J., Haeseleer F., Baehr B., Palczewski K. (2000).
Ca2+-Binding proteins in the retina: From discovery to etiology of human disease.
Biochim. Biophys. Acta 1498: 233-251. [PMID: 11108966]
56. Bressi J.C., Choe J., Hough M.T., Buckner F.S., Van Voorhis W.C., Verlinde C.L.M.J., Hol W.G.J., Gelb M.H. (2000).
Adenosine analogs as inhibitors of glycolytic enzymes of Trypanosoma brucei with the elucidation of a novel binding mode for a 2-amino-N6-substituted adenosine derivative to phosphoglycerate kinase.
J. Med. Chem. 43: 4135-4150. [PMID: 11063610]
55. Minke W.E., Pickens J., Merritt E.A., Fan E., Verlinde C.L.M.J.,Hol W.G.J. (2000).
Crystal structure of m-carboxyphenyl- -D-galactose complexed to heat-labile enterotoxin at 1.3 A resolution: surprising variation in ligand binding modes.
Acta Crystallogr. D56: 795-804. [PMID: 10930826]
54. Fan E., Zhang Z., Minke W.E., Hou Z., Verlinde C.L.M.J.,Hol W.G.J. (2000).
High affinity pentavalent ligands of E.coli heat-labile enterotoxin by modular structure-based design. J. Am. Chem. Soc.122: 2663-2664.
53. Haeseleer F., Sokal I., Verlinde C.L.M.J., Erdjument-Bromage H., Tempst P., Pronin A.N., Benovic J.L., Fariss R.N., Palczewski K. (2000).
Five members of a novel Ca(2+)-binding protein (CABP) subfamily with similarity to calmodulin.
J. Biol. Chem. 275: 1247-1260. [PMID: 10625670]


52. Michels P.A.M., Verlinde C.L.M.J. (1999).
Glycolytic enzymes. In "Encyclopedia of Life Sciences", Nature Publishing Group., London. [DOI: 10.1038/npg.els.0000621]
51. Diller D.J., Verlinde, C.L..M.J. (1999).
A critical evaluation of several global optimization algorithms for the purpose of molecular docking.
J. Comp. Chem. 20: 1740-1751.
50. Minke W.E., Hong F., Verlinde C.L.M.J., Hol W.G.J., Fan E. (1999).
Using a galactose library for exploration of a novel hydrophobic pocket in the receptor binding site of the E. coli heat-labile enterotoxin.
J. Biol. Chem. 274: 33469-33473. [PMID: 10559230]
49. Sokal I., Otto-Bruc A., Surgucheva I., Verlinde C.L.M.J., Wang C.K., Baehr W., Palczewski K. (1999).
Conformational changes in guanylyl cyclase-activating protein 1 (GCAP) and its tryptophan mutants as a function of calcium concentration.
J. Biol. Chem. 274: 19829-19837. [PMID: 10391927]
48. Minke W.E., Diller D.J., Hol W.G.J., Verlinde C.L.M.J. (1999).
The role of waters in docking strategies with incremental flexibility for carbohydrate derivatives: heat-labile enterotoxin, a multivalent test case.
J.Med.Chem.42: 1778-1788. [PMID : 10346930]
47. Minke W.E., Roach C., Hol W.G.J., Verlinde C.L.M.J. (1999).
Structure-based exploration of the ganglioside GM1 binding sites of E.coli heat-labile enterotoxin and cholera toxin for the discovery of receptor antagonists.
Biochemistry 38: 5684-5692. [PMID: 10231518]
46. Verlinde C.L.M.J., Quigley P.M. (1999).
Structure-based reevaluation of the mechanism of class I fructose-1,6-bisphosphate aldolase. J. Mol. Mod. 5: 37-45. [SPRINGER VERLAG: Abstract]
45. Aronov A.M., Buckner F.S., Van Voorhis W.C., Verlinde C.L.M.J., Opperdoes F.R., Hol W.G.J., Gelb M.H. (1999).
Structure-based design of sub-micromolar, biologically active inhibitors of trypanosomatid glyceraldehyde- 3-phosphate dehydrogenase.
Proc. Natl. Acad. Sci. USA96: 4273-4278. [PMID:10200252]
44. Palczewski K., Verlinde C.L.M.J., Haeseleer F. (1999).
Molecular mechanism of visual transduction. In 'Rhodopsins and photo-transduction' Novartis Foundation Symposium 224, Ed. Bock G., John Wiley & Sons, Chichester, pp. 191-207. [PMID: 10614052]
43. Hovey B., Verlinde C.L.M.J., Merritt E.A., Hol W.G.J. (1999).
Structure-based discovery of a pore- binding ligand: towards assembly inhibitors for cholera and related AB5 toxins.
J. Mol. Biol.285: 1168-1178. [PMID: 9887271]


42. Verlinde C.L.M.J. (1998).
Five Orders of Magnitude Affinity Gain in Anti-trypanosomal Drug Development. On-line Proceedings of the 5th Internet World Congress on Biomedical Sciences '98 at McMaster University, Canada [URL:]
40. Hol W.G.J., van den Akker F., Minke W., Hovey B., Feil I.K., Roach C., Sarafaty S.,Verlinde C.L.M.J., Merritt E.A. (1998).
Towards the design of drugs and vaccines on the basis of the three-dimensional structure of cholera toxin and E.coli heat-labile enterotoxin.
In 'Bacterial Protein Toxins', Zent. Bl. Bakteriol., Suppl. 29, Eds: Hacker et al., Gustav Fisher, Jena, Stuttgart, Lubeck, Ulm, pp. 17-23.
41. Aronov A.M., Verlinde C.L.M.J., Hol W.G.J., Gelb M.H. (1998).
Selective new inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design.
J. Med. Chem. 41: 4790-4799. [PMID: 9822549]


39. Verlinde C.L.M.J., Kim H., Bernstein B.E., van den Akker F., Minke W.E., Hovey B., Feil I.K., Sarfaty S., Roach C., Merritt E.A., Hol W.G.J. (1997).
Protein crystallography, tropical diseases and drug design.
In 'Rational Molecular Design in Drug Research - Alfred Benzon Symposium 42', Eds: Liljefors T., Jorgensen F.S., Krogsgaard-Larsen P. Munksgaard, Copenhagen, pp. 295-305.
38. Verlinde C.L.M.J., Kim H., Bernstein B.E., Mande S.C., Hol W.G.J. (1997).
Anti-trypanosomiasis drug development based on structures of glycolytic enzymes.
In 'Structure-based drug design', Ed. Veerapandian. Marcel Dekker, NY, pp. 365-394.


37. Buckner F.S., Verlinde C.L.M.J., La Flamme A.C. & Van Voorhis W.C. (1996).
Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.
Antimicrob. Agents Chemother. 40: 2592-2597. [PMID: 8913471]


36. Van Calenbergh S.,Verlinde C.L.M.J., Soenens J., De Bruyn A., Callens M., Blaton N.M., Peeters O.M., Hol W.G.J., Herdewijn P. (1995).
Synthesis and structure-activity relationships of analogs of 2'-deoxy- 2'-(3-methoxy-benzamido)adenosine, a selective inhibitor of trypanosomal glyceraldehyde phosphate dehydrogenase.
J. Med. Chem. 38: 3838-3849. [PMID : 7562915]
35. Verlinde C.L.M.J., Dijkstra B.W. (1995).
Drug or tool, design or serendipity?
Nature Struct. Biol. 2: 429-432. [PMID: 7664101]
34. Kim H., Feil I.K., Verlinde C.L.M.J., Petra P.H., Hol W.G.J. (1995).
Crystal structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Leishmania mexicana: Implications for structure-based drug design and a new position for the inorganic phosphate binding site.
Biochemistry34: 14975-14986. [PMID: 7578111]
33. Qiu X., Verlinde C.L.M.J. , Zhang S., Schmitt M.P.,Holmes R.K., Hol W.G.J. (1995).
Three-dimensional structure of the diphtheria toxin repressor in complex with divalent cation co-repressors.
Structure3: 87-100. [PMID: 7743135]


32. Verlinde C.L.M.J. , Merritt E.A., van den Akker F., Kim H., Feil I., Delboni L.F., Mande S.C., Sarfaty S., Petra P.H., Hol W.G.J. (1994).
Protein crystallography and infectious diseases.
Protein Sci. 3: 1670-1686. [PMID: 7849584]
31. Van Calenbergh S., Van Den Eeckhout E., Herdewijn P., De Bruyn A., Verlinde C., Hol W., Callens M., Van Aerschot A., Rozenski J. (1994).
Synthesis and conformational analysis of 2'-deoxy-2'- (3-methoxy- benzamido)adenosine, a rationally designed inhibitor of trypanosomal glyceraldehyde phosphate dehydrogenase.
Helv. Chim. Acta 77: 631-644.
30. Verlinde C.L.M.J., Callens M., Van Calenbergh S., Van Aerschot A., Herdewijn P., Hannaert V., Michels P.A.M., Opperdoes F.R., Hol W.G.J. (1994).
Selective inhibition of trypanosomal glyceraldehyde-3-phosphate dehydrogenase by protein structure-based design: Towards new drugs for the treatment of sleeping sickness.
J. Med. Chem. 37: 3605-3613. [PMID: 7932587]
29. Verlinde C.L.M.J. , Hol W.G.J. (1994).
Structure-based drug design: progress, results and challenges.

Structure 2: 577-587. [PMID: 7922037]


28. Verlinde C.L.M.J., Pijning T, Kalk K.H., van Calenbergh S., Van Aerschot A., Herdewijn P., Callens M., Michels P., Opperdoes F.R., Wierenga R.K., Hol W.G.J.
Protein structure-based inhibitor design: towards new drugs for sleeping sickness.
In 'Perspectives in Medicinal Chemistry. Proceedings of the XXIIth International Symposium on Medicinal Chemistry', Eds. Testa B., Kyburz E., Fuhrer W. & Giger R., Verlag Helvetica Chimica Acta, Basel, 1993, pp.135-148.
27. Vellieux F.M.D., Hajdu J., Verlinde C.L.M.J., Groendijk H., Read R.J., Greenhough T.J., Campbell J.W., Kalk K.H., Littlechild J.A., Watson H.C., Hol W.G.J. (1993).
Structure of glycosomal glyceraldehyde-3- phosphate dehydrogenase from Trypanosoma brucei determined from Laue data.
Proc. Natl. Acad. Sci. USA 90: 2355-2359. [PMID:8460146]


26. Verlinde C.L.M.J., Witmans C.J., Pijning T., Kalk K.H., Hol W.G.J., Opperdoes F.R. (1992).
Structure of the complex between trypanosomal triosephosphate isomerase and N-hydroxy-4-phosphono- butanamide: Binding at the active site despite an "open" flexible loop conformation.
Protein Sci. 1: 1578-1584. [PMID: 1304889]
25. Sander C., Vriend G., Bazan F., Horovitz A., Nakamura H., Ribas L., Finkelstein A.V., Lockhart A., Merkl M., Perry J., Emery S.C., Gaboriaud C., Marks C., Moult J., Verlinde C.L.M.J., Eberhard M., Elofsson A., Hubbard T.J.P., Regan L., Banks J., Jappelli R., Lesk A.M., Tramontano A. (1992).
Protein design on computers. Five new proteins: Shpilka, Grendel, Fingerclasp, Leather, and Aida.
Proteins: Structure, Function and Genetics 12: 105-110.
24. Verlinde C.L.M.J., Rudenko G., Hol W.G.J. (1992).
In search of new lead compounds for trypanosomiasis drug design: A protein structure-based linked-fragment approach.
J. Comput.-Aided Mol. Design 6: 131-147. [PMID: 1624956]


23. Hol W.G.J., Vellieux F.M.D., Verlinde C.L.M.J., Wierenga R.K., Noble M.E.M., Read R.J.
Crystallographic investigations of glycolytic enzymes from Trypanosoma brucei: potential starting points for the design of new sleeping sickness drugs.
In "Molecular conformation and biological interactions", Eds. Balaram P. & Ramaseshan, Indian Academy of Sciences, Bangalore, 1991, pp. 215-244.
22. Noble M.E.M., Verlinde C.L.M.J., Groendijk H., Kalk K.H., Wierenga R.K., Hol W.G.J.(1991).
Crystallographic and molecular modelling studies on trypanosomal triosephosphate isomerase: A critical assessment of the predicted and observed structures of the complex with 2-phosphoglycerate.
J. Med. Chem. 34: 2709-2718. [PMID: 1895291]
21. Verlinde C.L.M.J, Noble M.E.M., Kalk K.H., Groendijk H., Wierenga R.K., Hol W.G.J. (1991).
Anion binding at the active site of trypanosomal triosephosphate isomerase: Monohydrogen phosphate does not mimic sulphate.
Eur. J. Biochem. 198: 53-57. [PMID: 2040290]


20. Vellieux F.M.D., Wierenga R.K., Groendijk H., Read R.J., Noble M.E.M., Verlinde C.L.M.J., Hol W.G.J. (1990).
Protein crystallography and the design of new drugs against sleeping sickness.
In "Chemotherapy for Trypanosomiasis", Ed. Peregrine A.S., Nairobi, pp. 63-69.
19. Verlinde C.L., Peeters O.M., Blaton N.M., De Ranter C.J. (1990).
Structure of the opioid kappa-agonist (-)-(1R,5R,9R,2"S)-2'-hydroxy-2- (2-methoxypropyl)-5,9-dimethyl-6,7-benzomorphan Hydrobromide (I) and its inactive (-)-(1R,5R,9R,2"R) diastereomer (II).
Acta Cryst. C46: 663-666.
18. De Winter H.L., Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1990).
Structure of the neuroleptic drug 4-amino-N-1-[(1-ethyl-2-pyrollidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-benzamide (Amisulpride).
Acta Cryst. C46: 313-317. [PMID:1970258]
17. De Ranter C.J., Verlinde C.L.
Kappa-opioids in a Series of 6,7-Benzomorphans. Conformational Analysis and Pharmacophore Modelling,
in: Frontiers in Drug Research, Alfred Benzon Symposium 28, eds. Jensen B., Jorgensen,F.S. & Kofod H., Munksgaard, Copenhagen, 1990, pp. 30-44.


16. Peeters O.M., Verlinde C.L., Blaton N.M., De Ranter C.J.(1989).
Crystal structure and absolute configuration of two stereoisomers of , ' -(iminobis(methylene))-bis-(3,4-dihydro-2H-1-benzopyran-2-methanol) Hydrobromide.
Acta Cryst. C45: 1930-1933. [PMID: 2576841]
15. Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1989).
Structure and conformational analysis of the opioid antagonist (-)-(1R,5R,9R)-5,9-diethyl-2-(3-furylmethyl)-2'-hydroxy-6,7-benzomorphan (Mr2266).
Acta Cryst. C45: 1797-1802. [PMID: 2610966]
14. Verlinde C.L., Blaton N.M., De Ranter C.J., Peeters O.M. (1989).
Structure of a kappa-opioid receptor misfit: (1S,5R,8R,9R)-2'-hydroxy-5,9-dimethyl-8,2-epoxyethano-6,7-benzomorphan Hydrochloride.
Acta Cryst. C45: 799-803. [PMID: 2557866]
13. Verlinde C.L., De Ranter C.J. (1989).
Furan revisited: When to avoid ab initio studies on crystal structures.
J. Mol. Struct. (Theochem) 187: 161-167.
12. Verlinde C.L., De Ranter C.J., Blaton N.M., Peeters O.M. (1989).
Static disorder in (-)-(1R,5R,9R,13S)-2'-hydroxy-5,9- dimethyl-2-(2-methyl-tetrahydrofuryl)-6,7-benzomorphan: Crystal structure and MM2 pucker analysis of the tetrahydrofuran ring.
Acta Cryst. B45: 107-112.
11. Vanquickenborne L.G., Coussens B., Verlinde C., De Ranter C. (1989).
Ab initio analysis of 2-aminoethanol conformers, including electron correlation corrections for the energy.
J. Mol. Struct. (Theochem.) 201: 1-15.


10. Verlinde CL., Blaton N.M., Peeters O.M., De Ranter C.J. (1988).
(-)-(1R,5R,9R)-2'-hydroxy-2-methoxyethyl-5,9-dimethyl-6,7-benzomorphan Hydrobromide Monohydrate.
Acta Cryst. C44: 1792-1794.
9. Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1988).
(-)-(1R,5R,9R)-2-ethoxyethyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan Hydrobromide.
Acta Cryst. C44: 1789-1791.
8. Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1988).
(-)-(1R,5R,9R,2''R)-2'-hydroxy-5,9-dimethyl-2-[(tetrahydro-2-furyl)ethyl]-6,7-benzomorphan Hydrobromide.
Acta Cryst. C44: 1611-1614.
7. Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1988).
(-)-(1R,5R,9R)-2'-hydroxy-2-(3-methoxypropyl)-5,9-dimethyl-6,7-benzomorphan Hydrobromide Monohydrate.
Acta Cryst. C44: 1609-1611.
6. Blaton N.M., Vynckier S.M., Verlinde C.L., Peeters O.M., De Ranter C.J. (1988).
Structure of 8-chloro-2-[(3-furoyl)-amino-methyl]-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine Hydrochloride.
Acta Cryst. C44: 1125-1127.
5. Verlinde C.L., De Ranter C.J. (1988).
Assessment of the kappa-opioid activity of a series of 6,7-benzomorphans in the rabbit vas deferens.
Eur. J. Pharmacol. 153: 83-87. [PMID: 2850928]


No publications due to mandatory military service ...


4. De Ranter C.J., Verlinde C.L., Blaton N.M., Peeters O.M. (1985).
The role of oxygen in the opioid kappa-pharmacophore of some benzomorphans.
Arch.Int. Physiol. Biochem. 93: BP6.


3. De Ranter C.J., Verlinde C.L., Blaton N.M., Peeters O.M. (1984).
The kappa-active oxygen in the opioid pharmacophore of some benzomorphans: charges, proton affinities and binding modelling.
Neuropeptides 5: 209-212. [PMID: 6099499]
2. Verlinde C.L., Blaton N.M., De Ranter C.J., Peeters O.M. (1984).
5-ethyl-2'-hydroxy-2-[(1-hydroxy-cyclopropyl)-methyl)]-9,9-dimethyl-6,7-benzomorphan Hydrochloride (Bremazocine).
Acta Cryst. C40: 1759-1761.


1. Verlinde C.L., De Ranter C.J. (1983).
(1S,5R,9R)-2-cyclopropylmethyl-2'-hydroxy-5,9-dimethyl- 8-oxo-6,7-benzomorphan Hydrochloride Monohydrate (Ketazocine).
Acta Cryst. C39: 1703-1706.

Am I productive?

J.E. Hirsch published a new index to measure an individuals's scientific output, called the h-index. Reference: Hirsch J.E. (2005). An index to quantify an individual's scientific research output Proc. Natl. Acad. Sci. USA 102: 16569-16572. [PubMed: 16275915 ].

Definition: A scientist has index h if h of his/her Np papers have at least h citations each, and the other (Np - h) papers have no more than h citations each.

We can also define m as h divided by the length of a person's scientific career, assuming a simple linear model.

Hirsch writes "From inspection of the citation records of many physicists I conclude:
(1) A value m ~ 1, an h-index of 20 after 20 years of scientific activity, characterizes a successful scientist.
(2) A value m ~2, an h-index of 40 after 20 years of scientific activity, characterizes outstanding scientists, likely to be found only at the top universities or major research laboratories.
(3) A value m ~ 3 or higher, i.e. an h-index of 60 after 20 years, or 90 after 30 years, characterizes truly unique individuals."

For reference, in 2005 Edward Witten had the highest h-index in physics (110). In biology the h-indices seem to be higher, with an h-index for Solomon Snyder of 190, for David Baltimore 160, Bert Vogelstein 151 in 2005. For new inductees in the NAS USA in the biological and biomedical sciences the average h-index was 57.

In October 2017 my h-index was 41. I started research in 1982, with a 13 months hiatus along the way for mandatory military service in the Belgian army. My research was further interrupted in Nov. 2000 by several months because of kidney cancer, and in Oct 2002 because of paralysis due to CIDP. I spent 3 months in the hospital and I needed another 6 months to gear up to full research commitment. In total I lost 2 years, which reduces my research efforts to 35 years. My m value is 41/35=1.2, making me by Hirsch's criteria a "successful scientist".